Go Pro
NASDAQ:SINT

Sintx Technologies Q1 2026 Earnings Report

Sintx Technologies logo
$1.55 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern

Sintx Technologies EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.66
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Sintx Technologies Revenue Results

Actual Revenue
$0.38 million
Expected Revenue
$0.30 million
Beat/Miss
Beat by +$80.00 thousand
YoY Revenue Growth
N/A

Sintx Technologies Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Sintx Technologies' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Sintx Technologies Earnings Headlines

Research Analysts Set Expectations for SINT Q3 Earnings
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
See More Sintx Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sintx Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sintx Technologies and other key companies, straight to your email.

About Sintx Technologies

Sintx Technologies (NASDAQ:SINT) (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws. Sintx employs proprietary ceramic processing and additive manufacturing techniques to produce high-purity, high-density silicon nitride parts. This advanced material has demonstrated reduced bacterial adhesion, enhanced osteointegration and favorable imaging characteristics under X-ray and CT scanning compared with conventional metallic implants.

Founded in 2006 and headquartered in Salt Lake City, Utah, Sintx Technologies operates research and manufacturing facilities in the United States. The company has built a portfolio of patents covering silicon nitride composition, processing methods and medical device designs, and it collaborates with implant manufacturers, contract research organizations and academic institutions to advance clinical evaluation and regulatory approvals worldwide. Through distribution partnerships and OEM agreements, Sintx serves both domestic and select international markets, supporting early adopters in the spine and trauma segments as well as emerging applications in dental and orthobiologics.

Sintx is led by an executive team with experience in biomaterials, medical device development and regulatory affairs. The company continues to invest in R&D to expand its silicon nitride platform technology, pursuing new indications and commercial alliances that leverage the unique combination of strength, bioactivity and antimicrobial performance inherent in its ceramics.

View Sintx Technologies Profile